Esperion Therapeutics, Inc.ESPREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Wasatch Advisors LP | 12.60% | — | — | 2024-02-09 |
| BlackRock, Inc. | 7.30% | 14.3M | flat | 2024-11-08 |
| Two Seas Capital LP | 6.80% | 7.7M | ▼ -0.60pp | 2024-02-14 |
| The Vanguard Group | 6.64% | 13.0M | flat | 2024-11-12 |
| BB Biotech AG | 5.10% | 9.2M | ▲ +1.40pp | 2024-01-24 |
| The Statement is filed on behalf of each of the following persons | 3.30% | 6.6M | — | 2024-11-14 |
| Millennium Management LLC | 1.70% | 3.4M | ▼ -3.70pp | 2024-10-17 |
| Point72 Asset Management, L.P. | 0.10% | 4.8K | — | 2024-02-14 |
| Deep Track Capital, LP | 0.00% | 29.7K | — | 2024-02-14 |
| CVI Investments, Inc. | 0.00% | — | — | 2024-02-14 |
Insider Transactions
Net 90d: −$102.4K · buys $0 / sells $102.4KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-17 | Benjamin Halladay | Chief Financial Officer | Sell (open market) | 6.4K | $2.71 | $17.4K |
| 2026-03-17 | Benjamin Looker | Chief Legal Officer | Sell (open market) | 5.7K | $2.70 | $15.4K |
| 2026-03-17 | Koenig Sheldon L. | President and CEO | Sell (open market) | 25.6K | $2.72 | $69.5K |
| 2026-03-13 | Benjamin Looker | Chief Legal Officer | Grant | 300.8K | $0.00 | $0 |
| 2026-03-13 | Koenig Sheldon L. | President and CEO | Grant | 723.8K | $0.00 | $0 |
| 2026-03-13 | Benjamin Halladay | Chief Financial Officer | Grant | 247.4K | $0.00 | $0 |
1–6 of 6